Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSA/IL-2/GM-CSF vaccine for recurrent prostate cancer
NCT02058680Phase 1Unknown
- Sponsor
- OncBioMune Pharmaceuticals, Inc.
- Start
- Apr 2012
- Primary completion
- Dec 2018
- Modality
- Cytokines & Interferons, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of prostate-specific antigen + interleukin-2 + granulocyte-macrophage colony-stimulating factor in prostate cancer (PCa), sponsored by OncBioMune Pharmaceuticals, Inc. Status: unknown.
02
Drugs
prostate-specific antigen + interleukin-2 + granulocyte-macrophage colony-stimulating factor
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02058680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02058680.